Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H13N2O8.3Na |
Molecular Weight | 358.1881 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].[Na+].OC(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O
InChI
InChIKey=QZKRHPLGUJDVAR-UHFFFAOYSA-K
InChI=1S/C10H16N2O8.3Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;/q;3*+1/p-3
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C10H13N2O8 |
Molecular Weight | 289.2188 |
Charge | -3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.webmd.com/balance/tc/chelation-therapy-topic-overview#1 | https://www.empowerpharmacy.com/drugs/edetate-disodium-injection.htmlhttp://umm.edu/health/medical/altmed/supplement/ethylenediaminetetraacetic-acidCurator's Comment: description was created based on several sources, including, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm
Sources: https://www.webmd.com/balance/tc/chelation-therapy-topic-overview#1 | https://www.empowerpharmacy.com/drugs/edetate-disodium-injection.htmlhttp://umm.edu/health/medical/altmed/supplement/ethylenediaminetetraacetic-acid
Curator's Comment: description was created based on several sources, including, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm
Edetic acid (EDTA) is a chelating agent. The U.S. Food and Drug Administration (FDA) approved edetic acid chelation therapy as a treatment for lead and heavy metal poisoning. Edetic acid in form of disodium salt was withdrawn from the market due to death resulting from hypocalcemia during chelation.
Originator
Sources: https://www.researchgate.net/publication/321552574_Ferdinand_Munz_EDTA_and_40_years_of_inventionshttps://www.google.com/patents/US2130505
Curator's Comment: Edetic acid was synthesized by Ferdinand Munz.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: divalent and trivalent metals |
|||
Target ID: CHEMBL2364029 |
18.3 null [pKd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Calcium disodium versenate Approved UseEdetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Launch Date-5.19523205E11 |
|||
Curative | Calcium Disodium Versenate Approved UseEdetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Launch Date-5.19523205E11 |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
51 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3096624 |
1 g single, intramuscular dose: 1 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
EDETATE CALCIUM DISODIUM serum | Homo sapiens population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
60 min |
unknown, unknown |
EDETATE CALCIUM DISODIUM plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Co-administed with:: 2,3-dimercapto-1-propanol, i.v(3 mg/kg; 6/day; 5 days) Sources: |
unhealthy, 1-8 n = 130 Health Status: unhealthy Condition: Plumbism Age Group: 1-8 Sex: M+F Population Size: 130 Sources: |
Disc. AE: Acute renal failure... Other AEs: Nephrotoxicity... AEs leading to discontinuation/dose reduction: Acute renal failure (3%) Other AEs:Nephrotoxicity (mild, 13%) Sources: |
160 mg/kg single, intravenous Studied dose Dose: 160 mg/kg Route: intravenous Route: single Dose: 160 mg/kg Sources: Page: p.361 |
unhealthy, 49 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Multiple myeloma Age Group: 49 Sex: F Population Size: 1 Sources: Page: p.361 |
Disc. AE: Hypocalcemia... AEs leading to discontinuation/dose reduction: Hypocalcemia Sources: Page: p.361 |
400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
Disc. AE: Restlessness, Hypocalcemia... AEs leading to discontinuation/dose reduction: Restlessness Sources: Page: p.360Hypocalcemia |
400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache Sources: Page: p.360 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Acute renal failure | 3% Disc. AE |
25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Co-administed with:: 2,3-dimercapto-1-propanol, i.v(3 mg/kg; 6/day; 5 days) Sources: |
unhealthy, 1-8 n = 130 Health Status: unhealthy Condition: Plumbism Age Group: 1-8 Sex: M+F Population Size: 130 Sources: |
Nephrotoxicity | mild, 13% | 25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Co-administed with:: 2,3-dimercapto-1-propanol, i.v(3 mg/kg; 6/day; 5 days) Sources: |
unhealthy, 1-8 n = 130 Health Status: unhealthy Condition: Plumbism Age Group: 1-8 Sex: M+F Population Size: 130 Sources: |
Hypocalcemia | Disc. AE | 160 mg/kg single, intravenous Studied dose Dose: 160 mg/kg Route: intravenous Route: single Dose: 160 mg/kg Sources: Page: p.361 |
unhealthy, 49 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Multiple myeloma Age Group: 49 Sex: F Population Size: 1 Sources: Page: p.361 |
Hypocalcemia | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
Restlessness | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
Headache | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of ethylenediaminetetraacetic acid (EDTA) on acute mercury poisoning of toad. | 1986 |
|
Inhibition of carcinogen induced c-Ha-ras and c-fos proto-oncogenes expression by dietary curcumin. | 2001 |
|
Artificial iron-dependent proteases. | 2001 |
|
Evaluation of Er:YAG laser and EDTAC on dentin adhesion of six endodontic sealers. | 2001 |
|
Evaluation of copper availability to plants in copper-contaminated vineyard soils. | 2001 |
|
Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture--primary culture cells markedly differ from fourth-passage cells. | 2001 |
|
Chromosomal mapping, gene structure and characterization of the human and murine RAB27B gene. | 2001 |
|
Brain dystrophin-glycoprotein complex: persistent expression of beta-dystroglycan, impaired oligomerization of Dp71 and up-regulation of utrophins in animal models of muscular dystrophy. | 2001 |
|
Role of complement activation and mast cell degranulation in the pathogenesis of rapid intestinal ischemia/reperfusion injury in rats. | 2001 |
|
Purification and characterization of a phosphoric triester hydrolase from the tufted apple bud moth, Platynota idaeusalis (Walker). | 2001 |
|
Chemical speciation used to assess [S,S']-ethylenediaminedisuccinic acid (EDDS) as a readily-biodegradable replacement for EDTA in radiochemical decontamination formulations. | 2001 Apr |
|
Cloning and biochemical characterization of BglC, a beta-glucosidase from the cellulolytic actinomycete Thermobifida fusca. | 2001 Apr |
|
Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. | 2001 Feb |
|
Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. | 2001 Feb |
|
Prolonged stability of endogenous cardiotrophin-1 in whole blood. | 2001 Feb |
|
Estimation of glomerular filtration rate in cancer patients. | 2001 Feb |
|
Radiation sensitization of mammalian cells by metal chelators. | 2001 Feb |
|
Cabbage cryoprotectin is a member of the nonspecific plant lipid transfer protein gene family. | 2001 Feb |
|
Urea is a product of ureidoglycolate degradation in chickpea. Purification and characterization of the ureidoglycolate urea-lyase. | 2001 Feb |
|
Ethylenediamine-N,N,N',N'-tetraacetic acid induces parthenogenetic activation of porcine oocytes at the germinal vesicle stage, leading to formation of blastocysts. | 2001 Feb |
|
Glycoxidation and lipid peroxidation of low-density lipoprotein can synergistically enhance atherogenesis. | 2001 Feb 1 |
|
Influence of citrate and EDTA anticoagulants on plasma malondialdehyde concentrations estimated by high-performance liquid chromatography. | 2001 Feb 10 |
|
Comparative effects of metal chelating agents on the neuronal cytotoxicity induced by copper (Cu+2), iron (Fe+3) and zinc in the hippocampus. | 2001 Feb 16 |
|
Robustness of slope-intercept versus slope-only for measurement of glomerular filtration rate. | 2001 Jan |
|
Phagocytic response of bovine polymorphonuclear leukocytes to different incubation conditions and following exposure to some effectors of phagocytosis and different anticoagulants in vitro. | 2001 Jan |
|
Enhancement of jejunal absorption of conjugated bile acid by neurotensin in rats. | 2001 Jan |
|
Use of an orally administered combined sugar solution to evaluate intestinal absorption and permeability in cats. | 2001 Jan |
|
Flow cytometric analysis of the human articular chondrocyte phenotype in vitro. | 2001 Jan |
|
Comparison of lateral condensation and thermomechanically compacted warm alpha-phase gutta-percha with a single cone for obturating curved root canals. | 2001 Jan |
|
Poorly controlled hypertension in a painter with chronic lead toxicity. | 2001 Jan |
|
The value of MnDPDP enhancement during MR guided laser interstitial thermoablation of liver tumors. | 2001 Jan |
|
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. | 2001 Jan |
|
Statistical process monitoring of WBC-reduced blood components assessed by two types of software. | 2001 Jan |
|
Long-term preservation of chilled canine semen: effect of commercial and laboratory prepared extenders. | 2001 Jan 15 |
|
The occurrence of internal (1 --> 5)-linked arabinofuranose and arabinopyranose residues in arabinogalactan side chains from soybean pectic substances. | 2001 Jan 15 |
|
Multifunctional antioxidant activity of HBED iron chelator. | 2001 Jan 15 |
|
Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta. | 2001 Jan 26 |
|
Determination of metal complexes of ethylenediaminetetraacetate in the presence of organic matter by high-performance liquid chromatography. | 2001 Jan 5 |
|
Detection of bile duct leaks using MR cholangiography with mangfodipir trisodium (Teslascan). | 2001 Jan-Feb |
|
Mechanism of endothelin 1 production in the cochlea of rats. | 2001 Jan-Feb |
|
Measurement of intact insulin-like growth factor-binding protein-3 in human plasma using a ligand immunofunctional assay. | 2001 Mar |
|
Duration of sample storage dramatically alters expression of the human immunodeficiency virus coreceptors CXCR4 and CCR5. | 2001 Mar |
|
Adherence of Giardia lamblia trophozoites to Int-407 human intestinal cells. | 2001 Mar |
|
Pseudomonas aeruginosa protease IV enzyme assays and comparison to other Pseudomonas proteases. | 2001 Mar |
|
Kinetic modeling of liquid-phase adsorption of reactive dyes and metal ions on chitosan. | 2001 Mar |
|
Effect of collagenase inhibitors on corneal haze after PRK. | 2001 Mar |
|
The CDTA-soluble pectic substances from soybean meal are composed of rhamnogalacturonan and xylogalacturonan but not homogalacturonan. | 2001 Mar |
|
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
|
EDTA redistribution of lead and cadmium into the soft tissues in a human with a high lead burden - should DMSA always be used to follow EDTA in such cases? | 2011 Jun |
|
Lead mobilization study and the clearance of intravenous CaNa2EDTA in a patient with end-stage renal failure on hemodialysis. | 2012 Jan |
Sample Use Guides
hypercalcemia: adults: 50 mg/kg/day (up to 3 g/day) administered by slow IV infusion. Frequency and duration of administration are quite variable, and should be determined based on the patient's serum calcium. Five consecutive daily doses may be administered, followed by 2 days without medication, repeating these courses as necessary to a total of 15 doses.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:02:02 UTC 2023
by
admin
on
Fri Dec 15 15:02:02 UTC 2023
|
Record UNII |
420IP921MB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Official Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EPA PESTICIDE CODE |
39110
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
||
|
NCI_THESAURUS |
C360
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
205-758-8
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
PRIMARY | |||
|
756746
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
PRIMARY | |||
|
DTXSID7020556
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
PRIMARY | |||
|
63125
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
PRIMARY | |||
|
420IP921MB
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
PRIMARY | |||
|
105745
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
PRIMARY | RxNorm | ||
|
C76599
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
PRIMARY | |||
|
9008
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
PRIMARY | |||
|
m4835
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
PRIMARY | Merck Index | ||
|
420IP921MB
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
PRIMARY | |||
|
CHEMBL2028177
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
PRIMARY | |||
|
150-38-9
Created by
admin on Fri Dec 15 15:02:02 UTC 2023 , Edited by admin on Fri Dec 15 15:02:02 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
|
||
|
PARENT -> SALT/SOLVATE |
|